In this real-world study, fremanezumab demonstrated effectiveness for migraine regardless of migraine type or the presence of factors contributing to DTT migraine (MO, GAD, MDD, or prior exposure to a different CGRP mAb).
No takes yet. Share an insight, caveat, or question.
Driessen et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: